{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:21:19Z","timestamp":1761895279623,"version":"build-2065373602"},"reference-count":65,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":1317,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Center for Research Resources, National Institutes of Health","award":["CA090625-09"],"award-info":[{"award-number":["CA090625-09"]}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.bbmt.2011.05.002","type":"journal-article","created":{"date-parts":[[2011,5,12]],"date-time":"2011-05-12T14:30:21Z","timestamp":1305210621000},"page":"1265-1272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Treatment Options for Transformed Lymphoma: Incorporating Allogeneic Stem Cell Transplantation in a Multimodality Approach"],"prefix":"10.1016","volume":"17","author":[{"given":"Nishitha","family":"Reddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2011.05.002_bib1","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1182\/asheducation.V2009.1.532.532","article-title":"The incidence, natural history, biology, and treatment of transformed lymphomas","author":"Bernstein","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bbmt.2011.05.002_bib2","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdl162","article-title":"The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma","volume":"17","author":"Gine","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2011.05.002_bib3","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","article-title":"Population-based analysis of incidence and outcome of transformed non-Hodgkin\u2019s lymphoma","volume":"26","author":"Al-Tourah","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.05.002_bib4","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1200\/JCO.1997.15.4.1587","article-title":"Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients","volume":"15","author":"Bastion","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.05.002_bib5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/1097-0142(19830801)52:3<393::AID-CNCR2820520302>3.0.CO;2-M","article-title":"An autopsy study of histologic progression in non-Hodgkin\u2019s lymphomas. 192 cases from the National Cancer Institute","volume":"52","author":"Garvin","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2011.05.002_bib6","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3109\/10428191003793366","article-title":"Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications","volume":"51","author":"Ahmed","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2011.05.002_bib7","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.bbmt.2010.01.008","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review","volume":"16","author":"Oliansky","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.05.002_bib8","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2141.2006.06439.x","article-title":"Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms","volume":"136","author":"Davies","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2011.05.002_bib9","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2008-08-174839","article-title":"Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone","volume":"113","author":"Carlotti","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.05.002_bib10","first-page":"1405","article-title":"Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma","volume":"91","author":"Rossi","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2011.05.002_bib11","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/j.1582-4934.2008.00628.x","article-title":"Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma","volume":"13","author":"Lawrie","year":"2009","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.bbmt.2011.05.002_bib12","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2002-07-2119","article-title":"Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations","volume":"101","author":"Martinez-Climent","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.05.002_bib13","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1200\/JCO.2006.06.1648","article-title":"Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma","volume":"25","author":"Glas","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.05.002_bib14","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood-2009-07-235598","article-title":"The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation","volume":"115","author":"Farinha","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.05.002_bib15","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood-2006-04-018218","article-title":"High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma","volume":"108","author":"Carreras","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.05.002_bib16","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","article-title":"High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma","volume":"27","author":"Carreras","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.05.002_bib17","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1200\/JCO.2006.07.5671","article-title":"Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis","volume":"24","author":"Ghesquieres","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.05.002_bib18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s002770050503","article-title":"High-dose therapy and stem cell transplantation in follicular lymphoma","volume":"78","author":"Friedberg","year":"1999","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2011.05.002_bib19","first-page":"1236","article-title":"Management of nodal indolent (non marginal-zone) non-Hodgkin\u2019s lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation","volume":"90","author":"Barosi","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2011.05.002_bib20","first-page":"790","article-title":"Addition of rituximab to CHOP chemotherapy significantly improves survival of patients with transformed lymphoma","volume":"110","author":"Al-Tourah","year":"2007","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.bbmt.2011.05.002_bib21","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin\u2019s lymphoma: results from a phase II multicenter, single-agent study","volume":"26","author":"Friedberg","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.05.002_bib22","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdn657","article-title":"The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)","volume":"20","author":"Noy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2011.05.002_bib23","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1200\/JCO.1995.13.7.1726","article-title":"Long-term survival after histologic transformation of low-grade follicular lymphoma","volume":"13","author":"Yuen","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.05.002_bib24","first-page":"6476","article-title":"Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt\u2019s lymphoma xenografts","volume":"52","author":"Buchsbaum","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2011.05.002_bib25","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900.012k14_3900_3908","article-title":"Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in\u00a0vitro: CD55 and CD59 regulate complement-mediated cell lysis","volume":"95","author":"Golay","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.05.002_bib26","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.05.002_bib27","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1200\/JCO.2004.06.055","article-title":"Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"22","author":"Davies","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.05.002_bib28","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of\u00a0iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin\u2019s lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.05.002_bib29","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2000.18.6.1316","article-title":"Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed\/refractory low-grade and transformed low-grade B-cell non-Hodgkin\u2019s lymphomas","volume":"18","author":"Vose","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.05.002_bib30","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1200\/JCO.2005.07.040","article-title":"Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab","volume":"23","author":"Horning","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.05.002_bib31","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259","article-title":"Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience","volume":"96","author":"Kaminski","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.05.002_bib32","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1200\/JCO.2004.00.9217","article-title":"Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin\u2019s lymphomas","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.05.002_bib33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/10428190500260478","article-title":"Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan","volume":"47","author":"Fietz","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2011.05.002_bib34","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2011.05.002_bib35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bbmt.2004.11.017","article-title":"Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma","volume":"11","author":"Laudi","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.05.002_bib36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.bbmt.2005.10.006","article-title":"The role of hematopoietic cell transplantation for follicular non-Hodgkin\u2019s lymphoma","volume":"12","author":"Laport","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.05.002_bib37","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1046\/j.1365-2141.2001.02705.x","article-title":"Autotransplants for histologically transformed follicular non-Hodgkin\u2019s lymphoma","volume":"113","author":"Chen","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2011.05.002_bib38","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.bbmt.2007.04.009","article-title":"A 15-year analysis\u00a0of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma","volume":"13","author":"Sabloff","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.05.002_bib39","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1080\/10428190903128652","article-title":"High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphoma","volume":"50","author":"Smith","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2011.05.002_bib40","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.bbmt.2010.07.007","article-title":"Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomas","volume":"17","author":"Kasamon","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.05.002_bib41","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/sj.bmt.1705178","article-title":"Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma","volume":"36","author":"Andreadis","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.05.002_bib42","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1600-0609.2008.01146.x","article-title":"High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma","volume":"81","author":"Hamadani","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2011.05.002_bib43","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1023\/A:1008349427337","article-title":"High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre","volume":"9","author":"Foran","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2011.05.002_bib44","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2001.19.3.727","article-title":"High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin\u2019s lymphoma: a case-matched study from the European Bone Marrow Transplant Registry","volume":"19","author":"Williams","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.05.002_bib45","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood.V74.7.2579.2579","article-title":"Autologous bone marrow transplantation in follicular non-Hodgkin\u2019s lymphoma before and after histologic transformation","volume":"74","author":"Schouten","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.05.002_bib46","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.bbmt.2009.12.530","article-title":"Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large B-cell lymphoma: final results of a Phase II GOELAMS Study","volume":"16","author":"Dilhuydy","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.05.002_bib47","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/sj.leu.2404334","article-title":"Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents","volume":"20","author":"Barrett","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2011.05.002_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2011.01.016","article-title":"Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901","author":"Shea","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.05.002_bib49","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2141.2005.05755.x","article-title":"Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma","volume":"131","author":"Doocey","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2011.05.002_bib50","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin\u2019s lymphoma","volume":"26","author":"Rezvani","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.05.002_bib51","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3109\/10428194.2010.497981","article-title":"Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma","volume":"51","author":"Clavert","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2011.05.002_bib52","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2008.17.3328","article-title":"Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin\u2019s lymphoma","volume":"27","author":"Thomson","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.05.002_bib53","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.bbmt.2009.01.010","article-title":"Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-Hodgkin lymphomas","volume":"15","author":"Hamadani","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.05.002_bib54","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/bmt.2008.220","article-title":"Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results","volume":"42","author":"Ramadan","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.05.002_bib55","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1080\/10428190802270902","article-title":"Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma","volume":"49","author":"Hamadani","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2011.05.002_bib56","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.05.002_bib57","article-title":"Strategies to prevent EBV reactivation and post-transplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high risk patients","author":"Reddy","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.05.002_bib58","doi-asserted-by":"crossref","first-page":"6263","DOI":"10.1182\/blood-2009-04-213892","article-title":"Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD?","volume":"113","author":"Savani","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.05.002_bib59","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.seminhematol.2008.02.002","article-title":"Radioimmunotherapy-based conditioning regimens for stem cell transplantation","volume":"45","author":"Zhang","year":"2008","journal-title":"Semin Hematol"},{"key":"10.1016\/j.bbmt.2011.05.002_bib60","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJM199310213291702","article-title":"Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support","volume":"329","author":"Press","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2011.05.002_bib61","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2003-02-0622","article-title":"High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis","volume":"102","author":"Gopal","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.05.002_bib62","first-page":"330","article-title":"90Y Ibritumomab tiuxetan (Zevalin(R); 90YZ) doses calculated to deliver up to 1500 cGy to critical organs may be safely combined with high-dose BEAM and autotransplant in NHL","volume":"108","author":"Winter","year":"2006","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.bbmt.2011.05.002_bib63","first-page":"8013","article-title":"Radioimmunotherapy with 131-I tositumomab enhanced survival in good prognosis relapsed and high-risk diffuse large B-cell lymphoma (DLBCL) patients receiving high-dose chemotherapy and autologous stem cell transplantation","volume":"25","author":"Vose","year":"2007","journal-title":"ASCO Meet Abstr"},{"key":"10.1016\/j.bbmt.2011.05.002_bib64","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.bbmt.2006.03.014","article-title":"Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy","volume":"12","author":"Gopal","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.05.002_bib65","first-page":"315","article-title":"Efficacy and safety of yttrium 90 (90Y) ibritumomab tiuxetan in autologous and nonmyeloablative stem cell transplantation (NST) for relapsed non-Hodgkin\u2019s lymphoma (NHL)","volume":"108","author":"Khouri","year":"2006","journal-title":"ASH Annu. Meet. Abstr"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879111002084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879111002084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:39:32Z","timestamp":1761057572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879111002084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":65,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S1083879111002084"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2011.05.002","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Options for Transformed Lymphoma: Incorporating Allogeneic Stem Cell Transplantation in a Multimodality Approach","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2011.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}